Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model

Abstract

Patients with asthma with obesity experience severe symptoms, are unresponsive to conventional asthma treatment, and lack proper pharmacotherapy. Empagliflozin and dulaglutide, developed for diabetes, reduce weight, decrease insulin resistance, and exert additive effects. We evaluated the efficacy of empagliflozin, dulaglutide, and their combination on obesity-induced airway hyperresponsiveness (AHR) and lung fibrosis using a murine model. We assigned C57BL/6J mice to five groups: control, high-fat diet (HFD), and HFD with empagliflozin, dulaglutide, or both. Mice received a 12-week HFD, empagliflozin (5 days/week, oral gavage), and dulaglutide (once weekly, intraperitoneally). Both drugs significantly attenuated HFD-induced weight increase, abnormal glucose metabolism, and abnormal serum levels of leptin and insulin, and co-treatment was more effective. Both drugs significantly alleviated HFD-induced AHR, increased macrophages in bronchoalveolar lavage fluid (BALF), and co-treatment was more effective on AHR. HFD-induced lung fibrosis was decreased by both drugs alone and combined. HFD induced interleukin (IL)-17, transforming growth factor (TGF)-β1, and IL-1β mRNA and protein expression, which was significantly reduced by empagliflozin, dulaglutide, and their combination. Tumour necrosis factor (TNF)-α and IL-6 showed similar patterns without significant differences. HFD-enhanced T helper (Th) 1 and Th17 cell differentiation was improved by both drugs. Empagliflozin and dulaglutide could be a promising therapy for obesity-induced asthma and showed additive effects in combination.

Use of GLP1RAs and occurrence of respiratory disorders: A meta‐analysis of large randomized trials of GLP1RAs

“…Although better glucose control from GLP1RAs may lead to low incidence of pneumonia in T2D that cannot completely explain the benefits from GLP1RAs on all the nine kinds of respiratory conditions assessed in the study. In contrast, some possible mechanisms for the benefits from GLP1RAs on relevant respiratory diseases are revealed by several small sample human studies 12,13 and animal studies 14,15 in which GLP1RAs were observed to benefit for COPD, 12,13 airway hyperresponsiveness, 14 and acute lung injury 15 via immunomodulating and antiinflammatory effects.…”

Anisakis pegreffii Extract Induces Airway Inflammation with Airway Remodeling in a Murine Model System

“…The lung tissue samples were sectioned (2–3 μ m) and stained with hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) using standard histological protocols to detect mucus-containing cells [ 41 ]. Goblet cell hyperplasia was measured, and fibrosis was assessed, as previously described, using Masson's trichrome stain [ 42 ]. Tissue sections were examined using an Olympus BX53 microscope with an Olympus DP71 digital camera (magnification, 400x; Olympus DP71, Nishi Shinjuku 2-Chome, Tokyo, Japan).…”

Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders

“…Magnetic resonance elastography (MRE) has been used for assessing the stage and severity of liver fibrosis in diabetic patients via measuring liver stiffness [329,330]. [331]. Even though MRE and VCTE can assess liver stiffness, they only provide indications regarding the extent of liver fibrosis, corroborating the notion that only one type of imaging technique is insufficient to fully elucidate the fibrotic signature.…”